Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Morgan Stanley Downgrades Zentalis Pharmaceuticals(ZNTL.US) to Hold Rating, Cuts Target Price to $8
Maintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical Milestones
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
Zentalis Pharma Analyst Ratings
Oppenheimer Reiterates Outperform on Zentalis Pharma, Maintains $20 Price Target
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $20
Zentalis Pharmaceuticals Price Target Announced at $4.00/Share by Wedbush
Wells Fargo Sticks to Their Hold Rating for Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $20 Price Target
Buy Rating Affirmed for Zentalis Pharmaceuticals Amidst Clinical Progress and Regulatory Optimism
Oppenheimer Maintains Outperform on Zentalis Pharma, Lowers Price Target to $25
Zentalis Pharma Analyst Ratings
Wells Fargo Downgrades Zentalis Pharmaceuticals to Equal Weight From Overweight, Lowers Price Target to $9 From $29
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)